Navigation Links
Spherix Holds Annual Shareholders Meeting
Date:5/14/2008

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- At their 2008 Annual Meeting, shareholders of Spherix Incorporated (Nasdaq: SPEX) elected the following members to the Board of Directors:

-- Douglas T. Brown, Senior VP and Manager of Corporate Banking Government

Contracting, PNC Bank

-- A. Paul Cox, Jr., Principal, Asset Protection Company

-- Claire L. Kruger, Chief Executive Officer and Chief Operating Officer,

Spherix

-- Gilbert V. Levin, Ph.D., Director of Science and Technology, Spherix

-- Robert A. Lodder, Jr., President, Spherix; and Professor, College of

Pharmacy, University of Kentucky

-- Aris Melissaratos, Senior Advisor to the President of Johns Hopkins

University

-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods

International

In addition, Grant Thornton LLP was ratified as the Company's independent accountants for the year 2008.

Claire Kruger told the shareholders that Spherix management is focused and will continue to focus on the path forward necessary to bring Naturlose to market as a drug to treat Type 2 diabetes. To this end, three crucial activities are being undertaken in parallel:

1) Optimizing the efficiency and effectiveness of the clinical trial

program;

2) Evaluating the diabetes drug market potential to determine opportunity

and provide a clear understanding of our potential value;

3) Assuring supplies of tagatose, both the cGMP batches needed for the NDA

as well as a supplier to hold the Drug Master File once FDA approval

has been achieved.

At a Board of Directors meeting later the same day, the following slate of Corporate Officers was elected:

-- Paul Cox, Chairman of the Board

-- Claire Kruger, Chief Executive Officer and Chief Operating Officer

-- Robert Lodder, President

-- Robert Clayton, Interim Chief Financial Officer and Treasurer

-- Katherine Brailer, Corporate Secretary and Director of Administrative

Services

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is http://www.spherix.com.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Hires Key Employees
2. Spherix Reports 2007 Financial Results
3. Spherix Reports 3rd Quarter Earnings
4. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
5. Sinovac Biotech Holds Annual General Meeting
6. New Robotic Imaging Technology Holds Promise of Improved Cancer Care
7. Vion Pharmaceuticals Holds Special Meeting of Stockholders
8. Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network
9. Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing
10. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
11. CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 20, 2017 Bioptix, Inc. ... "Company"), announced that on January 14, 2017 the Board ... which the Company will terminate certain employees associated with ... Inc.  The Company commenced terminations on January 16, 2017 ... days.  The Company may pay severance benefits in certain ...
(Date:1/20/2017)... -- Ginkgo Bioworks, the organism company, announced today ... synthesis and assembly of DNA. The acquisition will ... DNA into Ginkgo,s automated organism engineering foundries, enabling ... new organism designs for application across a wide ... to significantly increase the world,s capacity to cost-effectively ...
(Date:1/19/2017)... LOUISVILLE, Ky. and HOUSTON ... Prenatal Inc. ("NX Prenatal") today announced the formation ... brings together leading clinicians and industry veterans who ... the company as it accelerates development of its ... positioned to provide medical, clinical and strategic guidance ...
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CESĀ® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
Breaking Biology News(10 mins):